MIRANSERTIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C27H24N6
Molecular Weight	432.5197
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC=CC=C1C2=NC3=CC=C(N=C3N2C4=CC=C(C=C4)C5(N)CCC5)C6=CC=CC=C6

InChI

InChIKey=HNFMVVHMKGFCMB-UHFFFAOYSA-N

InChI=1S/C27H24N6/c28-24-21(8-4-17-30-24)25-32-23-14-13-22(18-6-2-1-3-7-18)31-26(23)33(25)20-11-9-19(10-12-20)27(29)15-5-16-27/h1-4,6-14,17H,5,15-16,29H2,(H2,28,30)

HIDE SMILES / InChI

Molecular Formula	C27H24N6
Molecular Weight	432.5197
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.arqule.com/pipeline/arq-092/ | https://clinicaltrials.gov/ct2/show/NCT03094832 | https://www.ncbi.nlm.nih.gov/pubmed/30399177

Miransertib (ARQ 092) is a selective, pan-AKT (protein kinase B) inhibitor that potently inhibits AKT1, 2 and 3 isoforms. Miransertib binds inactive AKT, preventing membrane localization and subsequent AKT activation, and binds active AKT, resulting in direct inhibition. Miransertib participates in Phase 1/2 of clinical trials to treat patients at least 2 years of age with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS). In addition, the drug is involved in the phase I trial in patients with lymphoma, endometrial cancer, and AKT1 E17K mutations. Recently was shown that miransertib could be an excellent lead compound for the development of new oral drug therapy for visceral and cutaneous leishmaniasis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Serine/threonine-protein kinase AKT 29 Target ID: CHEMBL4282 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27305487	Inhibitor 8297	2.7 nM [IC50]
Serine/threonine-protein kinase AKT2 17 Target ID: CHEMBL2431 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27305487	Inhibitor 8297	14.0 nM [IC50]
Serine/threonine-protein kinase AKT3 17 Target ID: CHEMBL4816 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27305487	Inhibitor 8297	8.1 nM [IC50]

PubMed

Title	Date	PubMed
ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.	2017 Feb	27758820
Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma.	2018 Feb 16	29541403

Sample Use Guides

In Vivo Use Guide

ARQ 092 orally at 15 mg/m2 QD for the first 3 cycles on a 28 day schedule

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 01:49:46 UTC 2023` Edited by `admin` on `Sat Dec 16 01:49:46 UTC 2023`
Record UNII	T1DQI1B52Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MIRANSERTIB

Official Name

English

ARQ-092

Code

English

Miransertib [WHO-DD]

Common Name

English

2-PYRIDINAMINE, 3-(3-(4-(1-AMINOCYCLOBUTYL)PHENYL)-5-PHENYL-3H-IMIDAZO(4,5-B)PYRIDIN-2-YL)-

Systematic Name

English

3-(3-(4-(1-AMINOCYCLOBUTYL)PHENYL)-5-PHENYL-3H-IMIDAZO(4,5-B)PYRIDIN-2-YL)-2-PYRIDINAMINE

Systematic Name

English

ARQ092

Code

English

MIRANSERTIB [USAN]

Common Name

English

3-(3-(4-(1-AMINOCYCLOBUTYL)PHENYL)-5-PHENYL-3HIMIDAZO(4,5-B)PYRIDIN-2-YL)PYRIDIN-2-AMINE

Systematic Name

English

miransertib [INN]

Common Name

English

ARQ092 FREE BASE

Code

English

ARQ 092 [WHO-DD]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

497115